PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-27.92%
Negative net income growth while TRVN stands at 1.79%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
3.10%
D&A growth well above TRVN's 1.89%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
No Data
No Data available this quarter, please select a different quarter.
-10.46%
Both cut yoy SBC, with TRVN at -17.26%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
292.72%
Slight usage while TRVN is negative at -30.81%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
215.28%
A yoy AP increase while TRVN is negative at -5228.23%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
292.72%
Lower 'other working capital' growth vs. TRVN's 33227.56%. David Dodd would see fewer unexpected short-term demands on cash.
-67.58%
Negative yoy while TRVN is 4.95%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-21.90%
Both yoy CFO lines are negative, with TRVN at -2.07%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-11.48%
Negative yoy CapEx while TRVN is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-11.48%
Both yoy lines negative, with TRVN at -4.28%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
-59.52%
Both yoy lines negative, with TRVN at -100.00%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.